GW642444
Sponsors
GlaxoSmithKline
Conditions
AsthmaPulmonary Disease, Chronic Obstructive
Phase 1
A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects.
CompletedNCT00671216
Start: 2008-05-20End: 2008-07-07Updated: 2017-10-04
A Study to Investigate the Effect of Inhaling Single Doses of Different Formulations of GW642444M in Asthmatic Patients
CompletedNCT00702910
Start: 2008-04-27End: 2008-10-04Updated: 2017-08-10
A Study To Investigate Safety, Blood Levels And Effects Of Giving GW642444, By Mouth, By Inhalation & By Injection
CompletedNCT00711126
Start: 2008-10-21End: 2008-12-17Updated: 2017-07-21
A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects
CompletedNCT00783003
Start: 2008-11-10End: 2009-02-06Updated: 2017-07-18
Phase I Study of GW642444M in Healthy Japanese Male Subjects
CompletedNCT00964249
Start: 2008-09-20End: 2008-12-01Updated: 2017-08-03
Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW642444 Are Processed by the Body in Healthy Subjects
CompletedNCT01299558
Start: 2010-05-17End: 2010-07-15Updated: 2017-06-12
Phase 2
Investigation Of A New Medication (GW642444) In Asthmatic Patients
CompletedNCT00354874
Start: 2005-01-31End: 2005-06-30Updated: 2016-09-15
A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT00372112
Start: 2006-11-03End: 2007-05-10Updated: 2018-04-02
Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects
CompletedNCT01453296
Start: 2010-08-31End: 2011-04-30Updated: 2017-01-13